Gastroenterology

Treatment with terlipressin led to better long-term clinical outcomes for patients with hepatorenal syndrome who received a liver transplant.

On-demand vonoprazan at all investigated doses was significantly better than placebo in providing rapid and sustained relief from heartburn episodes in patients with nonerosive reflux disease.

Weekly dupilumab 300 mg versus placebo demonstrated statistically significant, clinically meaningful improvements in histologic and endoscopic outcomes and symptoms in adults and adolescents with eosinophilic esophagitis.

The approval of risankizumab represents the first IL-23 approved for IBD.

A 30 mg dose of upadacitinib led to a 1 month longer clinical remission and approximately 20% of patients had less severe disease at 52 weeks, when compared with a 15 mg dose for patients with active ulcerative colitis.

The study results are consistent with previous meta-analyses that show the efficacy of FMT in patients with IBD compared to placebo.

Bezlotoxumab is a fully humanized monoclonal antibody approved by the US Food and Drug Administration in 2017 for the prevention of recurrent CDI.

Dr. Chopra elaborated on his Pri-Med Midwest 2022 presentation regarding the future of advances in medicine, specifically highlighting artificial intelligence, gut microbiome research, and gene editing.

Dr. Chopra described several key points of his Pri-Med Midwest presentation regarding the future of advances in medicine, including artificial intelligence, gut bacteria, and CRISPR technology.

A discussion with Dr. Vega regarding colorectal cancer screenings, aspirin use recommendations, and the current state of healthcare.

The slight benefit could be attributed to a lower than expected adherence to screening requests.

An increase of 1 microgram/m3 in PM2.5 or 1% in toxic releases equates to an increase in the IBS incidence rate of about 0.02 cases per 100 person-years.

The risk of primary composite cardiovascular outcomes was reduced by 47%, while the risk of secondary cardiovascular disease outcomes was reduced by 50% in patients with bariatric surgery compared to nonsurgical patients.

The new recommendations call for posterior partial fundoplication over total posterior or anterior 90° fundoplication in adult patients with GERD and anterior >90° fundoplication as an alternative.

Vedolizumab was linked to an increased risk of treatment failure compared to TNF antagonists.

The approval is based on data from 2 clinical trials showing the agent improved the rate of post-operation patients avoiding sickness by 50%.

While cesarean delivery was more likely among women with IBD, this was not associated with an increased risk of peripartum infection.

The magnitude of the difference in modified Mayo score from baseline was significantly greater in all ABX464 groups compared to placebo.

The investigators found no significant differences when trainees participated in the ADR, CIR, and perforation rate compared to when trainees did not participate.

IBS-type symptoms were not linked to an increased likelihood of the need for glucocorticosteroids or flare, escalation, hospitalization, or intestinal resection.

Contamination was 11.5% on floors, 7.9% on infusion chairs, and 3.8% on equipment.

The most common complaint among patients was abdominal pain followed by diarrhea.

Symptom flare-ups in patients on a gluten-free diet were significantly lower than in patients on a high-gluten diet.

The 10-year cumulative incidences for HCC and mortality were significantly higher in the HBV cohort with heavy alcoholism than it was for either HBV alone or alcoholism alone.

Investigators articulated the development and validation of an enzyme-linked immunoassay against hepatitis C virus (HCV). They suggest the implementation of this low cost assay among at-risk populations.